Description
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Location: CPMC (San Francisco)
Please contact: ClinicalResearch@sutterhealth.org about study Alexion ALXN2050 MG